Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL8552735 | 0.64 | HDAC1 (0.37) | — | |
| Maleic Acid SCHEMBL8551457 | 0.63 | HTR1F (0.41) | — | |
| Maleic Acid SCHEMBL7140325 | 0.63 | HDAC1 (0.46) | — | |
| Maleic Acid SCHEMBL8551151 | 0.62 | HDAC1 (0.36) | — | |
| Maleic Acid SCHEMBL8190943 | 0.62 | HTR1F (0.59) | — | |
| Maleic Acid SCHEMBL7143351 | 0.58 | HDAC1 (0.40) | — | |
| SCHEMBL27550431 | 0.53 | NNMT (0.41) | — | |
| SCHEMBL10618800 | 0.52 | CYP1A2 (0.40) | — | |
| Fumaric Acid SCHEMBL28211218 | 0.52 | CAPN1 (0.49) | — | |
| Fumaric Acid SCHEMBL5157986 | 0.51 | ALDH1A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-6696439-B1 | HETEROCYCLIC IMINES SUCH AS 2-METHYL-3-(2-(N',N'-DIETHYLAMINO) ETHYL)-5-(4-PROPANESULFONYLBENZAMIDE)FURO(3,2-B)PYRIDINE, HYDROCHLORIDE, USED AS SEROTONIN RECEPTOR ANTAGONISTS FOR PROPHYLAXIS OF HEADACHES | ELI LILLY AND COMPANY | 2004-02-24 | — | — | US | disclosed |
| EP-1155020-B1 | FURO[3,2-B]PYRIDINES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |